Thanks to their particular expertise in health authorities and the CPP (Comité de Protection des Personnes), which gives them a constant anchoring in the practice and new issues of the sector, both in terms of drugs and medical devices, ELSI's lawyers intervene on all questions relating to the regulation of clinical trials and assist sponsors and investigators in their dealings with the authorities.
In addition to regulatory aspects, ELSI also deals with liability issues and assists its clients with contractual issues related to clinical trials (mandate contract, single agreement, etc.), as well as with the development of research.
Following the Jardé Law n° 2012-300 of 5 March 2012 on research involving the human person, and its implementing decrees, the clinical research framework is once again undergoing major changes, encouraged both by the desire to make the sector more attractive in France and by the contributions of new European texts.
First of all, the regulatory framework for research on medicinal products has undergone major upheaval with the entry into force of the European Regulation on clinical trials, which repeals Directive 2001/20/EC on clinical trials and simplifies the procedures for sponsors through the creation of a one-stop European shop, the centralised Internet portal (CTIS ), where clinical trial applications and the publication of results are submitted at a single point in the European Union. The timetables for scientific and ethical evaluation by the ANSM and the CPPs have also been simplified, as have the procedures for intervention by the competent authorities.
While non-interventional studies and clinical investigations involving cosmetics and medical devices (MDs) are excluded from this new legal framework, the MD and IVD sector must adapt to the Regulations of 5 April 2017 in terms of both clinical investigations and the newclinical evaluation requirements.
The diversification of the different types of studies and research requested by the health and reimbursement authorities (real-life studies, use of clinical databases and/or the National Health Data System (SNDS), quality of life, patient registers, etc.) and the question of the framework within which they are to be conducted.) and the question of the framework in which they are conducted also drive the issues in this sector.
In this context, the classification and qualification of the types of studies, the processing of personal data and related health data, the methods of collecting these data, recruiting and informing patients, communication, the supply of products, the new requirements of transparency, vigilance, in a constantly evolving context with regard to the field of possibilities, particularly technical, are all questions that any industrialist, CRO, sponsor or investigator must face and for which the assistance of a lawyer specialising in clinical trials may be necessary. This is why our law firm, specialised in health products and clinical trials, assists its clients in the strategy and legal security of all aspects of the life cycle of their products.
Marketing, advertising, health police, establishments, anti-gift & transparency+
Contract law, commercial, advertising, distribution, restrictive practices, anti-competitive practices+
ELSI provides its expertise in advising, supporting and defending the interests of its clients, both in the development of their strategy and in amicable and contentious proceedings.+
GDPR, CNIL methodology, health data hosting
securing contracts, support for digital projects
Legal and regulatory updates, skills upgrading, find out about all our tailor-made offers+
Our outsourcing offer, the subcontracting of your anti-gift activities & health transparency+
Subscriptions to regulatory advice, audit packages, find out about all our subscription and subcontracting offers+
Transformation, temporary surge, implementation of new processes, crisis management+
An investigation by the DGCCRF in 2021 led to the penalization of 6.6 million euros for illegal practices by the URGO group.
Medical device law
An amendment to the WDR has just been proposed by the European Commission to postpone the entry into force of the WDR.